The Hindu Business Line : Aurobindo depression drug gets nod

Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Sertraline Hydrocholride oral concentrate in 20 mg. The drug is the generic equivalent of Pfizer’s Zoloft oral concentrate. It is indicated for the treatment of major depressive disorder in adults. The approval was the 82nd abbreviated new drug approval for the Hyderabad-based company, according to a release.

— Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
BEML declares 65% final dividend

BEL pays 147% final dividend

Daiichi Sankyo completes Ranbaxy buy

‘Time to look for M&A opportunities’

Gujarat NRE Coke setting up new plant in AP

OVL yet to get nod from Russia for Imperial takeover

Aurobindo depression drug gets nod

Elgi Equipments forms venture with German co

Centre for Asia-Pacific Aviation to set up $250-m venture fund

Corus to further cut output by 30%; 400 jobs to go

JSW Steel to cut output by 20% in Nov

Cement firms’ cost of production rises 17 pc in Q2

More companies opt to trim man hours, cut production

Essar Minerals gets new CEO

BHEL R&D unit has new Executive Director